JTC-801

JTC-801
JTC-801
JTC-801.png
임상자료
기타 이름JTC-801
식별자
  • N-(4-아미노-2-메틸퀴놀린-6-yl)-2-[(4-에틸페녹시)메틸]벤츠아미드
CAS 번호
펍켐 CID
IUPHAR/BPS
켐스파이더
유니
화학 및 물리적 데이터
공식C26H25N3O2
어금질량411.505 g·1905−1
3D 모델(JSmol)
  • O=C(c1ccc1COc2ccc(cc2)CC)Nc3ccc4nc(cc(c4c3)N)c
  • InChI=1S/C26H25N3O2/c1-3-18-8-11-21(12-9-18)31-16-19-6-4-5-7-22(19)26(30)29-20-10-13-25-23(15-20)24(27)14-17(2)28-25/h4-15H,3,16H2,1-2H3,(H2,27,28)(H,29,30) ☒N
  • 키:VTGBZWHPJFMTKS-UHFFFAOYSA-N ☒N
☒NcheckY (이게 뭐야?) (iii)

JTC-801은 과학 연구에 사용되는 오피오이드 진통제다.[1][2]

JTC-801은 ORL-1 수용체라고도 알려진 Nociceptin 수용체에 대한 선택적 길항제다.[3] 이것은 발견된 네 번째 오피오이드 수용체였고 여전히 가장 덜 이해되고 있다. nociceptin 수용체는 통증과 염증 반응에 관련된 많은 과정에 관여하는 복합적인 효과를 가지고 있으며, 이 수용체의 활성화는 투여량에 따라 통증을 증가시키거나 감소시킬 수 있다.[4] 노이시셉틴 수용체에서 작용하는 약물은 NSAID,[5] μ-오피오이드 작용제,[6] 카나비노이드와 같은 전통적인 진통제의 효과에 영향을 미칠 수 있다.[7]

JTC-801은 구강 활성 약물로, 다양한 동물 연구에서 nociceptin 수용체를 차단하고 진통 효과를 내는 약으로, 특히 신경손상과 관련된 신경통알로디니아에 유용하다.[8][9][10]

참고 항목

참조

  1. ^ Shinkai H, Ito T, Iida T, Kitao Y, Yamada H, Uchida I (November 2000). "4-Aminoquinolines: novel nociceptin antagonists with analgesic activity". Journal of Medicinal Chemistry. 43 (24): 4667–77. doi:10.1021/jm0002073. PMID 11101358.
  2. ^ Yamada H, Nakamoto H, Suzuki Y, Ito T, Aisaka K (January 2002). "Pharmacological profiles of a novel opioid receptor-like1 (ORL(1)) receptor antagonist, JTC-801". British Journal of Pharmacology. 135 (2): 323–32. doi:10.1038/sj.bjp.0704478. PMC 1573142. PMID 11815367.
  3. ^ Sestili I, Borioni A, Mustazza C, Rodomonte A, Turchetto L, Sbraccia M, et al. (December 2004). "A new synthetic approach of N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide (JTC-801) and its analogues and their pharmacological evaluation as nociceptin receptor (NOP) antagonists". European Journal of Medicinal Chemistry. 39 (12): 1047–57. doi:10.1016/j.ejmech.2004.09.009. PMID 15571866.
  4. ^ Muratani T, Minami T, Enomoto U, Sakai M, Okuda-Ashitaka E, Kiyokane K, et al. (October 2002). "Characterization of nociceptin/orphanin FQ-induced pain responses by the novel receptor antagonist N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl) benzamide monohydrochloride". The Journal of Pharmacology and Experimental Therapeutics. 303 (1): 424–30. doi:10.1124/jpet.102.036095. PMID 12235279. S2CID 1162524.
  5. ^ Okuda-Ashitaka E, Minami T, Matsumura S, Takeshima H, Reinscheid RK, Civelli O, Ito S (February 2006). "The opioid peptide nociceptin/orphanin FQ mediates prostaglandin E2-induced allodynia, tactile pain associated with nerve injury". The European Journal of Neuroscience. 23 (4): 995–1004. doi:10.1111/j.1460-9568.2006.04623.x. PMID 16519664. S2CID 39006891.
  6. ^ Zaveri N, Jiang F, Olsen C, Polgar W, Toll L (October 2005). "Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): ligand-based analysis of structural factors influencing intrinsic activity at NOP". The AAPS Journal. 7 (2): E345-52. doi:10.1208/aapsj070234. PMC 2750971. PMID 16353914.
  7. ^ Rawls SM, Schroeder JA, Ding Z, Rodriguez T, Zaveri N (August 2007). "NOP receptor antagonist, JTC-801, blocks cannabinoid-evoked hypothermia in rats". Neuropeptides. 41 (4): 239–47. doi:10.1016/j.npep.2007.03.001. PMID 17512052. S2CID 19443938.
  8. ^ Mabuchi T, Matsumura S, Okuda-Ashitaka E, Kitano T, Kojima H, Nagano T, et al. (April 2003). "Attenuation of neuropathic pain by the nociceptin/orphanin FQ antagonist JTC-801 is mediated by inhibition of nitric oxide production". The European Journal of Neuroscience. 17 (7): 1384–92. doi:10.1046/j.1460-9568.2003.02575.x. PMID 12713641. S2CID 36588304.
  9. ^ Suyama H, Kawamoto M, Gaus S, Yuge O (November 2003). "Effect of JTC-801 (nociceptin antagonist) on neuropathic pain in a rat model". Neuroscience Letters. 351 (3): 133–6. doi:10.1016/S0304-3940(03)00502-0. PMID 14623124. S2CID 20099481.
  10. ^ Tamai H, Sawamura S, Takeda K, Orii R, Hanaoka K (March 2005). "Anti-allodynic and anti-hyperalgesic effects of nociceptin receptor antagonist, JTC-801, in rats after spinal nerve injury and inflammation". European Journal of Pharmacology. 510 (3): 223–8. doi:10.1016/j.ejphar.2005.01.033. PMID 15763246.